DuBiotech Drives UAE Regulatory Development

March 2006 | Company Finance Alert

However, Israel offers a marked contrast. Approximately 35% of all civilian research is undertaken in the life sciences sector. In 2004, 30% of all Israeli scientists were in the life sciences, while around 35% of civilian R&D is in this field. In addition, scientific institutions such as the Weizmann Institute have drug commercialisation offices to help bring products to market. As a result Israel has seen a surge in the number of life science companies established in the past decade. If DuBiotech can stimulate similar growth in the UAE and Middle East Region than it will be viewed as

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.